Shares of AstraZeneca (AZN.LN) were up 0.1% in after-hours trading on Tuesday after a company executive testified before Congress that the drug maker expects to deliver 50 million of its experimental COVID-19 vaccine in the U.S. in April if it's authorized before then. That would be enough to vaccinate 25 million people. AstraZeneca's COVID-19 vaccine has been authorized for use in some other countries, including the U.K.; however, it is currently in phase 3 clinical studies in the U.S. "Based on current projections, assuming [emergency use authorization], we expect to deliver up to 50 million doses by the end of April," Ruud Dobber, president of North America business for AstraZeneca, told members of the House Subcommittee on Oversight and Investigations on Tuesday, according to a spokesperson. The trial finished enrollment in January but the company has not yet released any clinical data for the U.S. arm of the study. AstraZeneca's stock is down 0.2% over the past 12 months, while the broader S&P 500 is up 16.1%.
Any recommendation, opinion or advice regarding securities or markets contained in such material does not reflect the views of TD Ameritrade, and TD Ameritrade does not verify any information included in such material.